Ripretinib

Jump to navigation Jump to search

Ripretinib
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alen Antony Pathil, M.D.[2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Ripretinib is a kinase inhibitor that is FDA approved for the treatment of Gastrointestinal stromal tumor in adults who have been already treated with # or more kinase inhibitors, including imatinib.. Common adverse reactions include alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia, and vomiting.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Ripretinib FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

The recommended dosage of ripretinib is 150 mg orally once daily with or without food until disease progression or unacceptable toxicity.

The tablet is swallowed as whole and should be taken on the same time each day. The patients are also advised to take the missed dose earliest if the missed dose is less than 8hrs, and advised to not take additional doses if they develop vomiting.

If they develop any adverse effects, reduce the dosage to 100 mg once daily. However, if they can't tolerate 100 mg, it should be completely discontinued.


Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Ripretinib FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Contraindications

There is limited information regarding Ripretinib Contraindications in the drug label.

Warnings

There is limited information regarding Ripretinib Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Ripretinib Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Ripretinib Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Ripretinib Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Ripretinib in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ripretinib in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Ripretinib during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Ripretinib in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Ripretinib in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Ripretinib in geriatric settings.

Gender

There is no FDA guidance on the use of Ripretinib with respect to specific gender populations.

Race

There is no FDA guidance on the use of Ripretinib with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Ripretinib in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Ripretinib in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Ripretinib in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Ripretinib in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Ripretinib Administration in the drug label.

Monitoring

There is limited information regarding Ripretinib Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Ripretinib and IV administrations.

Overdosage

There is limited information regarding Ripretinib overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Ripretinib Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Ripretinib Mechanism of Action in the drug label.

Structure

There is limited information regarding Ripretinib Structure in the drug label.

Pharmacodynamics

There is limited information regarding Ripretinib Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Ripretinib Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Ripretinib Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Ripretinib Clinical Studies in the drug label.

How Supplied

There is limited information regarding Ripretinib How Supplied in the drug label.

Storage

There is limited information regarding Ripretinib Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Ripretinib |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Ripretinib |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Ripretinib Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Ripretinib interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Ripretinib Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Ripretinib Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.